Gary Barnett, Central Park Tower, and the Tel Aviv Stock Exchange Bull (Credit: Wikipedia, iStock)Another New York real estate developer is attracting concerned looks from the Israeli bond market, as the coronavirus epidemic has brought construction and sales in the city to a near halt.A week after Related Companies’ bonds were downgraded, Gary Barnett’s Extell Development saw its bonds given a negative projection by rating agency Midroog, according to a disclosure published Sunday on the Tel Aviv Stock Exchange.“The rating has been placed under credit review as a result of the spread of coronavirus around the world and particularly in New York, which is expected to impact the company’s pace of sales, its cash flows, and the progress of development projects,” the agency’s announcement states.Read moreRelated tries to calm Israeli investors after market panic2018: Gary Barnett facing rising backlash in Israel over $75M payoutExtell bonds downgraded in Israel, but remain low risk Extell did not respond to a request for comment.Statewide orders by the Cuomo administration have forced the developer to close sales offices at all of its projects and work has stopped at the Central Park Tower, which topped out in September. The ultra-luxury sector is particularly vulnerable to deterioration in this macroeconomic environment, Midroog notes.Extell’s bonds are rated A3. Any further downgrade would bring the rating into B territory, characteristic of “speculative” investments.Midroog previously downgraded Extell’s bonds from A2 to A3 in 2017, citing New York City’s softening luxury market as a primary factor. In 2018, Extell faced a bondholder lawsuit and an investigation from the Israel Securities Authority amid concerns about the firm’s liquidity.Last week, Related Companies’ Israeli bonds were downgraded from A+ to BBB by Standard & Poor’s after an annual earnings report revealed concerns about its ability to repay maturing bonds during a financial crisis.Extell’s bonds are now trading at about 76 cents on the dollar, down nearly 25 percent from the start of the year. That is even worse than the 16 percent decline of the Tel Bond Global index — which tracks foreign bond issuers, including many New York-based real estate firms — over the same period.Extell Series B bond price over the past three months (Credit: Tel Aviv Stock Exchange) This content is for subscribers only.Subscribe Now
Raul Gonzalez extends his adventure at Paris Saint-Germain until June 2023! And this paves the road for Nikola to go to PSG… Alfons 8. June 2015. at 12:39 Recommended for you PSG Handball suffered first defeat in domestic Championship 2020/2021 1 Comment Related Items:PSG Handball, Zvonimir Noka Serdarusic UNSTOPPABLE! PSG HANDBALL 21/21 in France! 1 Comment ShareTweetShareShareEmailCommentsAfter having achieved three great seasons at Paris Saint-Germain Handball, highlighted by two French Division 1 titles, two French cups and one Trophée des Champions, the adventure has come to an end between Philippe Gardent and the club, this following a unique national performance. Present since day one of the new era at Paris Saint-Germain, Philippe Gardent has managed to get the best out of his team in all competitions, with a quarter-final in the EHF Champions league for the first time.Thierry Perreux, assistant coach, remains at the club in order to bring his savoir-faire and will coordinate the youth team and the first team.A new era has now begun and Paris Saint-Germain Handball is delighted to announce the nomination of Zvonimir Noka Serdarusic as head coach for two seasons. He will take charge of the team when training resumes, on the 21st of July.As a former international player, Zvonimir Serdarusic has made most of his career in ex-Yougoslavia as a line player, where he won 5 national championship titles before pursuing his career in Germany. In 1984, at the age of 34, the Mostar raised and born (Bosnia-Herzegovina) puts an end to his career and returns to his home country in order to coach for two years the team that saw him start as a player, Velez Mostar.But it is at THW Kiel where he spent time from 1993 to 2008 that his tremendous reputation and great career was built. He managed to turn THW Kiel from random to the most successful German team and one of the best in Europe. He won 11 German championship titles, 5 German cups and 4 German Supercups. On the international level, he secured 3 EHF titles before winning the Champions League in 2007.In September 2013, « Noka » joins Pays d’Aix Université Club Handball as a club advisor. Following a dismissal at Pays d’Aix, he then became the head coach of the southern club until recently.source: PSG Handball ShareTweetShareShareEmail Leave a Reply Cancel replyYour email address will not be published.Comment Name Email Website Save my name, email, and website in this browser for the next time I comment.
In decades of work, no treatment has been discovered for ALS that can do anything but prolong human survival less than a month. The mouse model used in this study is one that scientists believe may more closely resemble the human reaction to this treatment, which consists of a compound called copper-ATSM.It’s not yet known if humans will have the same response, but researchers are moving as quickly as possible toward human clinical trials, testing first for safety and then efficacy of the new approach.ALS was identified as a progressive and fatal neurodegenerative disease in the late 1800s, and gained international recognition in 1939 when it was diagnosed in American baseball legend Lou Gehrig. It’s known to be caused by the death and deterioration of motor neurons in the spinal cord, which in turn has been linked to mutations in copper, zinc superoxide dismutase.Copper-ATSM is a known compound that helps deliver copper specifically to cells with damaged mitochondria, and reaches the spinal cord where it’s needed to treat ALS. This compound has low toxicity, easily penetrates the blood-brain barrier, is already used in human medicine at much lower doses for some purposes, and is well tolerated in laboratory animals at far higher levels. Any copper not needed after use of copper-ATSM is quickly flushed out of the body.Experts caution, however, that this approach is not as simple as taking a nutritional supplement of copper, which can be toxic at even moderate doses. Such supplements would be of no value to people with ALS, they said.The new findings were reported by scientists from OSU; the University of Melbourne in Australia; University of Texas Southwestern; University of Central Florida; and the Pasteur Institute of Montevideo in Uruguay. The study is available as open access in Neurobiology of Disease.Using the new treatment, researchers were able to stop the progression of ALS in one type of transgenic mouse model, which ordinarily would die within two weeks without treatment. Some of these mice have survived for more than 650 days, 500 days longer than any previous research has been able to achieve.In some experiments, the treatment was begun, and then withheld. In this circumstance the mice began to show ALS symptoms within two months after treatment was stopped, and would die within another month. But if treatment was resumed, the mice gained weight, progression of the disease once again was stopped, and the mice lived another 6-12 months.In 2012, Beckman was recognized as the leading medical researcher in Oregon, with the Discovery Award from the Medical Research Foundation of Oregon. He is also director of OSU’s Environmental Health Sciences Center, funded by the National Institutes of Health to support research on the role of the environment in causing disease.“We have a solid understanding of why the treatment works in the mice, and we predict it should work in both familial and possibly sporadic human patients,” Beckman said. “But we won’t know until we try.”Familial ALS patients are those with more of a family history of the disease, while sporadic patients reflect the larger general population.“We want people to understand that we are moving to human trials as quickly as we can,” Beckman said. “In humans who develop ALS, the average time from onset to death is only three to four years.”The advances are based on substantial scientific progress in understanding the disease processes of ALS and basic research in biochemistry. The transgenic mice used in these studies have been engineered to carry the human gene for “copper chaperone for superoxide dismutase,” or CCS gene. CCS inserts copper into superoxide dismustase, or SOD, and transgenic mice carrying these human genes die rapidly without treatment.After years of research, scientists have developed an approach to treating ALS that’s based on bringing copper into specific cells in the spinal cord and mitochondria weakened by copper deficiency. Copper is a metal that helps to stabilize SOD, an antioxidant protein whose proper function is essential to life. But when it lacks its metal co-factors, SOD can “unfold” and become toxic, leading to the death of motor neurons.There’s some evidence that this approach, which works in part by improving mitochondrial function, may also have value in Parkinson’s disease and other conditions, researchers said. Research is progressing on those topics as well.The treatment is unlikely to allow significant recovery from neuronal loss already caused by ALS, the scientists said, but could slow further disease progression when started after diagnosis. It could also potentially treat carriers of SOD mutant genes that cause ALS. Share on Twitter Share Share on Facebook Pinterest Email Researchers at Oregon State University announced today that they have essentially stopped the progression of amyotrophic lateral sclerosis (ALS), or Lou Gehrig’s disease, for nearly two years in one type of mouse model used to study the disease – allowing the mice to approach their normal lifespan.The findings, scientists indicate, are some of the most compelling ever produced in the search for a therapy for ALS, a debilitating and fatal disease, and were just published in Neurobiology of Disease.“We are shocked at how well this treatment can stop the progression of ALS,” said Joseph Beckman, lead author on this study, a distinguished professor of biochemistry and biophysics in the College of Science at Oregon State University, and principal investigator and holder of the Burgess and Elizabeth Jamieson Chair in OSU’s Linus Pauling Institute. LinkedIn